PUBLICATIONS

PUBLICATIONS

  • 10

    Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease

    Journal of Hepatology. 2025. Impact factor: 33.0

    Joo Hyun Oh, Eileen L. Yoon, Huiyul Park, Seungmin Lee, Ae Jeong Jo, Seon Cho, Eunjoo Kwon, Eun-Hee Nah, Jun-Hyuk Lee, Jung Hwan Park, Sang Bong Ahn, Dae Won Jun

    Link
  • 9

    Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort

    Journal of Hepatology. 2024. Impact factor: 33.0

    Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun

    Link
  • 8

    Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?

    Journal of Hepatology. 2021. Impact factor: 33.0

    Huiyul Park, Eileen L. Yoon, Seon Cho, Eun-Hee Nah, Dae Won Jun

    Link
  • 7

    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.

    GUT. 2021. Impact factor: 23.0

    Huiyul Park, Eileen L Yoon, Seon Cho, Dae Won Jun, Eun-Hee Nah

    Link
  • 6

    Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis

    Clinical and Molecular Hepatology. 2024. Impact factor: 16.9

    Hee Yeon Kim, Jung Hwan Yu, Young Eun Chon, Seung Up Kim, Mi Na Kim, Ji Won Han, Han Ah Lee, Young Joo Jin, Ji Hyun An, Mi Young Choi, Dae Won Jun

    Link
  • 5

    KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease

    Clinical and Molecular Hepatology. 2024. Impact factor: 16.9

    Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young Joo Jin, Seung seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, Young Rok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)

    Link
  • 4

    Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings

    Hepatology. 2024. Impact factor: 15.8

    Chul-Min Lee, Eileen L Yoon, Mimi Kim, Bo-Kyeong Kang, Seon Cho, Eun-Hee Nah, Dae Won Jun

    Link
  • 3

    Is lifestyle modification effective for individuals with high fibrosis-4 index without an additional 2nd tier test?

    Hepatology. 2023. Impact factor: 15.8

    Huiyul Park, Eileen L Yoon, Mimi Kim, Sun-Hong Kwon, Dae Won Jun, Hye-Lin Kim

    Link
  • 2

    Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study

    Clinical Gastroenterology and Hepatology. 2023. Impact factor: 12.6

    Angela Chau, Ming-Lun Yeh, Pei-Chien Tsai, Daniel Q Huang, Sung Eun Kim, Huy Trinh, Eileen L Yoon, Hyunwoo Oh, Jae Yoon Jeong, Sang Bong Ahn, Jihyun An, Cheng-Hao Tseng, Yao-Chun Hsu, Soung Won Jeong, Yong Kyun Cho, Jae-Jun Shim, Hyoung Su Kim, Takanori Ito, Sebastián Marciano, Keigo Kawashima, Takanori Suzuki, Tsunamasa Watanabe, Akito Nozaki, Toru Ishikawa, Kaori Inoue, Yuichiro Eguchi, Haruki Uojima, Hiroshi Abe, Hirokazu Takahashi, Makoto Chuma, Masatoshi Ishigami, Joseph K Hoang, Mayumi Maeda, Chung-Feng Huang, Adrian Gadano, Chia-Yen Dai, Jee-Fu Huang, Yasuhito Tanaka, Wan-Long Chuang, Seng Gee Lim, Ramsey Cheung, Ming-Lung Yu, Dae-Won Jun, Mindie H Nguyen 

    Link
  • 1

    Nomenclature dilemma of metabolic associated fatty liver disease (MAFLD): Considerable proportions of MAFLD are metabolic healthy

    Clinical Gastroenterology and Hepatology. 2022. Impact factor: 12.6

    Huiyul Park, Eileen L Yoon, Mimi Kim, Seon Cho, Eun-Hee Nah, Dae Won Jun

    Link